Quest Diagnostics Incorporated (DGX)

Gross profit margin

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Gross profit (ttm) US$ in thousands 2,901,000 2,931,000 3,052,000 3,103,000 3,295,000 3,549,000 3,780,000 3,921,000 4,049,000 4,338,000 4,478,000 4,137,000 3,633,000 3,026,000 2,512,000 2,594,000 2,689,000 2,631,000 2,606,000 2,594,000
Revenue (ttm) US$ in thousands 9,100,000 9,153,000 9,351,000 9,467,000 9,745,000 10,142,000 10,425,000 10,520,000 10,628,000 10,932,000 10,982,000 10,297,000 9,437,000 8,361,000 7,531,000 7,657,000 7,726,000 7,639,000 7,572,000 7,538,000
Gross profit margin 31.88% 32.02% 32.64% 32.78% 33.81% 34.99% 36.26% 37.27% 38.10% 39.68% 40.78% 40.18% 38.50% 36.19% 33.36% 33.88% 34.80% 34.44% 34.42% 34.41%

December 31, 2023 calculation

Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $2,901,000K ÷ $9,100,000K
= 31.88%

Quest Diagnostics, Inc.'s gross profit margin has shown a downward trend over the past eight quarters. The company's gross profit margin decreased from 38.21% in Q1 2022 to 33.00% in Q4 2023. This decline may indicate challenges in controlling the cost of goods sold relative to revenue generated. The decreasing trend in gross profit margin could also signal potential pricing pressures or inefficiencies in the company's operations. It is important for Quest Diagnostics to closely monitor and analyze its cost structure to maintain a healthy level of profitability and strategic positioning in the market.


Peer comparison

Dec 31, 2023

Company name
Symbol
Gross profit margin
Quest Diagnostics Incorporated
DGX
31.88%
Fulgent Genetics Inc
FLGT
36.12%
Laboratory Corporation of America Holdings
LH
27.05%
RadNet Inc
RDNT
93.06%